Tab. 3.

Cross-comparisons of the C values from the SLS models, using unpaired two-sample t-tests (separate variances). For duration, the distributions were strongly skewed by the subjects presenting very long-duration saccades at the highest drug concentrations. Thus, together with the t-test, it is reported the p-value of a Mann-Whitney 2-sample test.

CROSS-COMPARISONS PEAK VELOCITY [eq. 1] (n=60)
Groups	Propof. Vs Placebo	Midaz. Vs Placebo	Dexmed. Vs Placebo	Midaz. Vs Propof.	Dexmed. Vs Propof.	Dexmed. Vs Midaz.
Difference	−0.035*	−0.032*	−0.017*	0.003	0.018*	0.015*
t-value	−6.2	−5.5	−3.4	0.4	3.2	2.6
Prob	1×10−8	3×10−7	0.001	0.7	0.001	0.009

CROSS-COMPARISONS DURATION [eq. 2] (n=60)
Groups	Propof. Vs Placebo	Midaz. Vs Placebo	Dexmed. Vs Placebo	Midaz. Vs Propof.	Dexmed. Vs Propof.	Dexmed. Vs Midaz.
Difference	0.149*	0.135*	0.100*	−0.014	−0.049	−0.035
t-value	3.8	6.4	4.9	−0.4	−1.1	−1.2
Prob	3×10−4	4×10−9	3×10−6	0.7	0.3	0.2
Mann- Whitney	3×10−9	9×10−14	5×10−9	0.04	0.97	0.04

CROSS-COMPARISONS RECIPROCAL OF LATENCY [eq. 3] (n=60)
Groups	Propof. Vs Placebo	Midaz. Vs Placebo	Dexmed. Vs Placebo	Midaz. Vs Propof.	Dexmed. Vs Propof.	Dexmed. Vs Midaz.
Difference	−0.044*	−0.041*	−0.027*	0.003	0.017*	0.014*
t-value	−6.9	−6.9	−4.4	1.0	4.2	4.0
Prob	6×10−10	2×10−9	4×10−5	0.3	6×10−5	1×10−4

CROSS-COMPARISONS GAIN PRIMARY SACCADE [eq. 4] (n=60)
Groups	Propof. Vs Placebo	Midaz. Vs Placebo	Dexmed. Vs Placebo	Midaz. Vs Propof.	Dexmed. Vs Propof.	Dexmed. Vs Midaz.
Difference	−0.018*	−0.029*	−0.003	−0.011*	0.015*	0.026*
t-value	−5.9	−8.1	−0.9	−2.6	4.1	6.4
Prob	4×10−8	2×10−12	0.4	0.01	6×10−5	4×10−9